

ALVARO CASTELLANOS M. & CIA.
A B O G A D O S
Calle 94 A No. 7A - 09
A.A. 6349
Bogotá, D.C., COLOMBIA

271

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
Rad: 05-088702-00002-0000 Pac: 2006-05-10 15:31:17
Dep. 2020 NUECREACIONES
Tne: 11 PATENTEEYU Ene 378 FASENACIONALJ
Act 329 CTOINFORMACION Folios: 4

Señor

Jefe de la División de Nuevas Creaciones

Superintendencia de Industria y Comercio

Ministerio de Comercio, Desarrollo, Industria y Turismo

E. S. D.

Ref.: Expediente No. 05.088.702

Solicitud de Patente de Invención Fase Nacional para:

"COMPUESTOS DE PIRAZOL"

Solicitante: **SUMITOMO CHEMICAL COMPANY LIMITED**

COMPLEMENTO DE INFORMACION

MARGARITA CASTELLANOS ABONDANO, mayor de edad, identificada y domiciliada como aparece al pie de mi firma, atentamente me permito presentar la copia en inglés de la opinión escrita de la Búsqueda Internacional, de ésta opinión se puede apreciar que la Oficina Internacional encontró que las reivindicaciones 1 a 15 cumplen con los requisitos de novedad, nivel inventivo y aplicación industrial.

En consecuencia, atentamente solicito a Ud. se anexe dicha opinión al expediente correspondiente a esta solicitud de Patente de Invención.

Señor Jefe,


Margarita Castellanos Abondano
C.C. No. 39.779.654 de Usaquén
T.P.A. No. 70.819 del Consejo Superior de la Judicatura
Calle 94 A No. 7 A-09 – Bogotá, D.C.
Teléfonos: 6107420 – 6107480

Bogotá, D.C. **10 MAYO 2006**
MCAV

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:

PCT

Translation

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis 1)

Date of mailing
(day month year)

Applicant's or agent's file reference

563078

FOR FURTHER ACTION

See paragraph 2 below

International application No.

PCT/JP2004/001071

International filing date (day month year)

03.02.2004

Priority date (day month year)

25.03.2003

International Patent Classification (IPC) or both national classification and IPC

Applicant

SUMITOMO CHEMICAL COMPANY, LIMITED

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA JP

Authorized officer

Facsimile No.

Telephone No.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

273
International application No.

PCT/JP2004/001071

Box No. 1

Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
☐ This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material
☐ a sequence listing
☐ table(s) related to the sequence listing
 - b. format of material
☐ in written format
☐ in computer readable form
 - c. time of filing/furnishing
☐ contained in the international application as filed.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

279

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2004/001071

Box No. V

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement

1. Statement

Novelty (N)

Claims 1-15

YES

Claims

NO

Inventive step (IS)

Claims 1-15

YES

Claims

NO

Industrial applicability (IA)

Claims 1-15

YES

Claims

NO

2. Citations and explanations:

Document 1: JP. 8-208551, A (Sumitomo Chemical Co., Ltd.), 13 August, 1996 (13.08.96)

Document 2: EP. 648729, A1 (Sumitomo Chemical Co., Ltd.), 19 April, 1995 (19.04.95)

Document 3: JP, 2001-354639, A (Kureha Chemical Industry Co., Ltd.), 25 December, 2001
(25.12.01)

Claims 1-15

The subject matters of claims 1-15 appear to be novel and to involve an inventive step in view of documents 1-3 cited in the ISR.

Documents 1-3 neither describe nor suggest the compounds of the invention of the present application, i.e., the compounds of the general formula (a) stated in the claims of the present application or the compounds of the general formula (b) also stated in the claims as intermediate products used for producing the compounds of the general formula (a).